--- title: "Emcitate (tiratricol) in MCT8 deficiency: cost-effectiveness analyses and utility weights" description: "Published cost-effectiveness analyses and health-state utility weights for Emcitate (tiratricol) in MCT8 deficiency, each value quoted from the article: 0 cost-effectiveness analyses and 2 studies reporting utility weights. Utility weights: Utility weights by Gross Motor Function Classification level with severe cognitive impairment, and caregiver disutilities, early juvenile metachromatic leukodystrophy: Bean et al. (2024); Utility weights by intellectual outcome category, congenital hypothyroidism: Appelberg et al. (2023). Every value is a verbatim quote from the primary article it is shown with." canonical: "https://www.evicenter.com/drugs/emcitate--mct8-deficiency/cost-effectiveness-analyses" published: "2026-10-22T07:49:06-04:00" modified: "2026-10-22T07:49:06-04:00" --- # Emcitate (tiratricol) in MCT8 deficiency: cost-effectiveness analyses and utility weights Published cost-effectiveness analyses and health-state utility weights that a model of this product could cite, adapt, or compare against, grouped by how each article relates to the product and its indication. Every value is quoted from the article it cites, and section 3 lists the searches that found the articles. ## Overview | Item | Detail | | --- | --- | | Literature searched | Tufts Medical Center Cost-Effectiveness Analysis Registry, searched October 21, 2026; the queries are listed in section 3. | | Cost-effectiveness analyses | 0 | | Studies reporting utility weights | 2 | ## 1 Cost-effectiveness analyses ### 1.1 Analyses of Emcitate (tiratricol) No evidence found. ### 1.2 Treatments for the same indication No evidence found. ### 1.3 The same disease in other populations or settings No evidence found. ### 1.4 Related diseases and analogous treatments No evidence found. ## 2 Utility weights ### 2.1 Utility weights from analyses of Emcitate (tiratricol) No evidence found. ### 2.2 Utility weights for the same indication No evidence found. ### 2.3 Utility weights for the same disease in other populations or settings No evidence found. ### 2.4 Utility weights for related diseases and analogous treatments #### Utility weights by Gross Motor Function Classification level with severe cognitive impairment, and caregiver disutilities, early juvenile metachromatic leukodystrophy: Bean et al. (2024) Relevance: Utilities by Gross Motor Function Classification level with severe cognitive impairment, and caregiver disutilities by level, from a UK general-population vignette study used in a model of early juvenile metachromatic leukodystrophy, a genetic childhood neurological disorder whose motor function states correspond to the absent head control, sitting, and walking reported for MCT8 deficiency in section 2.2.1.8.1. > “Utility values to calculate QALYs associated with the long-term benefits and disease progression arms were generated from a vignette study conducted in the UK general population (n = 201).” > “The UK general population evaluated the quality of life of patients in the later stages of disease to be worse than death, generating negative utility values” > “In addition, a caregiver disutility was included for patients in GMFC-MLD 3 to 6 to capture the negative effect on health-related quality of life that caring for an MLD patient has on their families.” Source: [Bean et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11270184/) | Health state | Utility, early juvenile, severe cognitive impairment | Total caregiver disutility | | --- | --- | --- | | “GMFC-MLD 0” | “0.51” | “0” | | “GMFC-MLD 1” | “0.42” | “0” | | “GMFC-MLD 2” | “0.34” | “0” | | “GMFC-MLD 3” | “−0.05” | “−0.108” | | “GMFC-MLD 4” | “−0.36” | “−0.108” | | “GMFC-MLD 5” | “−0.43” | “−0.216” | | “GMFC-MLD 6” | “−0.49” | “−0.216” | Source: [Bean et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11270184/) #### Utility weights by intellectual outcome category, congenital hypothyroidism: Appelberg et al. (2023) Relevance: Utilities by intellectual outcome category from a decision-analytic model of newborn screening for phenylketonuria and congenital hypothyroidism, a disorder of thyroid hormone supply to the developing brain, an outcome dimension that corresponds to the severe psychomotor impairment described for MCT8 deficiency in section 2.2.1.8.1. Access: Not open access Not quoted: The utility weights are reported in the full text, which this page does not quote. > “A decision-analytic model was developed to estimate and compare the long-term (80 years) costs and health effects of newborn screening for PKU and congenital hypothyroidism.” Source: [Appelberg et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36495999/) ## 3 Search strategy | Dataset | Query | Results | | --- | --- | --- | | Ratios | tiratricol OR "Triac" OR Emcitate | 0 | | Methods | tiratricol OR Emcitate | 0 | | Ratios | "MCT8" OR "Allan-Herndon-Dudley" OR "monocarboxylate transporter" | 0 | | Weights | "MCT8" OR "Allan-Herndon-Dudley" OR "thyroid hormone transport" | 0 | | Ratios | "thyroid hormone" AND (levothyroxine OR propylthiouracil) | 2 | | Ratios | "congenital hypothyroidism" | 17 | | Ratios | "Rett syndrome" OR trofinetide OR "CDKL5" OR ganaxolone | 0 | | Weights | "Rett syndrome" OR "CDKL5" OR "Angelman" OR "Dravet" | 9 | | Ratios | "metachromatic leukodystrophy" OR "adrenoleukodystrophy" OR "Krabbe" OR "Canavan" OR "Pelizaeus" | 12 | | Weights | "metachromatic leukodystrophy" OR "adrenoleukodystrophy" OR "leukodystrophy" | 39 | | Weights | "cerebral palsy" OR "Gross Motor Function Classification" | 86 | | Weights | "hyperthyroidism" OR "thyrotoxicosis" | 39 | | Weights | "intellectual disability" OR "developmental delay" OR "psychomotor" | 22 | | Ratios | levothyroxine OR propylthiouracil | 9 | | Methods | DITPA OR diiodothyropropionic OR "thyroid hormone analogue" OR "thyroid hormone analog" | 0 | ## Related pages - [Emcitate (tiratricol): MCT8 deficiency](https://www.evicenter.com/drugs/emcitate--mct8-deficiency) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency.md) - [Emcitate (tiratricol) in MCT8 deficiency: Terms and abbreviations](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/terms-and-abbreviations.md) - [Emcitate (tiratricol): MCT8 deficiency](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/executive-summary) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/executive-summary.md) - [Emcitate (tiratricol) in MCT8 deficiency: Product information and disease description](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/product-information-and-disease-description.md) - [Emcitate (tiratricol) in MCT8 deficiency: Clinical evidence](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/clinical-evidence.md) - [Emcitate (tiratricol) in MCT8 deficiency: Economic information and modeling report](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/economics) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/economics.md) - [Emcitate (tiratricol) in MCT8 deficiency: References](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/references) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/references.md) - [Emcitate (tiratricol) in MCT8 deficiency: new drug review](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/monograph/review) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/monograph/review.md) - [Emcitate (tiratricol) in MCT8 deficiency: prevalence by geography](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/prevalence) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/prevalence.md)